RJA
GNOM icon

Raymond James & Associates’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Raymond James & Associates’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,409
Closed -$213K – 4200
2021
Q3 		$213K Buy
+2,409
New +$226K ﹤0.01% 3632

Other funds holding GNOM

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BS
Banco Santander Madrid, Spain $12.4B AUM 29.42% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Raymond James & Associates's GNOM Position: Q4 2021 in Review

Raymond James & Associates sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2021, closing a stake of 2,409 shares — an estimated $213K sold.

Raymond James & Associates first reported a position in GNOM in Q3 2021 and held it in 1 quarter. The position peaked at $213K in Q3 2021. 61 funds tracked by Wall St. Rank hold GNOM as of Q4 2021.

  • Raymond James & Associates reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 2,409 Global X Genomics & Biotechnology ETF shares in Q4 2021, an estimated $213K.
  • Raymond James & Associates first reported a position in Global X Genomics & Biotechnology ETF in Q3 2021 and held it in 1 quarter.
  • Raymond James & Associates's Global X Genomics & Biotechnology ETF position peaked at $213K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.